DMRA
Damora Therapeutics, Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.56B
P/E Ratio
—
EPS
$-2.68
Beta
1.51
52W High
$38.33
52W Low
$2.45
50-Day MA
$24.79
200-Day MA
$18.69
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Damora Therapeutics, Inc.
Damora Therapeutics, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company is headquartered in Copenhagen, Denmark.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-64.75M |
| Operating Margin | 0.00% |
| Return on Equity | -89.50% |
| Return on Assets | -14.70% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $6.29 |
| Price-to-Book | 4.11 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | 0.46 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $61.55M |
| Float | $40.80M |
| % Insiders | 7.69% |
| % Institutions | 91.04% |
Historical Volatility
HV 10-Day
48.33%
HV 20-Day
52.49%
HV 30-Day
46.09%
HV 60-Day
69.49%
HV Rank
—
Volatility is currently expanding
Analyst Ratings
Consensus ($44.50 target)
1
Strong Buy5
BuyMore HEALTHCARE Stocks
Data last updated: 5/25/2026